NCT04950621

Remimazolam and Endovascular Procedures of Cerebrovascular Diseases

Comparison of Efficacy and Safety of Remimazolam and Propofol in Patients Undergoing Endovascular Procedures of Cerebrovascular Disorders: A Single-center,Randomized,Single-blind, Non-inferiority Trial

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 142 (actual)
• Sponsor: Air Force Military Medical University, China · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Remimazolam, a novel ultra-short acting benzodiazepine that combined the advantages of midazolam and remifentanil, has been developed for procedural sedation, induction and maintenance of general anesthesia, and sedation in the ICU. Previous studies have suggested that efficacy and safety of remimazolam are not inferior to propofol or midazolam in patients undergoing colonoscopy,bronchoscopy and some other treatments. However, the efficacy and potential adverse effects of remimazolam on patients undergoing endovascular procedures of cerebrovascular disorders is still unclear. In this study, we tend to conduct a single-center, randomized, single-blind ,non-inferiority trial to compare the efficacy and safety of remimazolam and propofol in endovascular procedures of cerebrovascular disorders.

Conditions

• Cerebrovascular Disorders
• Anesthesia

Interventions

Type	Name	Description
DRUG	remimazolam	Remimazolam will be administered during induction and maintenance for general anesthesia.
DRUG	propofol	Propofol will be administered during induction and maintenance for general anesthesia.

Timeline

• Start date: 2021-07-13
• Primary completion: 2022-06-30
• Completion: 2022-09-30
• First posted: 2021-07-06
• Last updated: 2022-10-20

Locations

1 site across 1 country: China